"Yet to See True Next Leg of Growth" - BMO Capital Keeps Gilead Sciences (GILD) at Market Perform

BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $63.00 price target on Gilead Sciences (NASDAQ: GILD), following the company's most recent quarterly report.

The analyst comments: 'Looking ahead to TIGIT data + details on a path forward for Trodelvy in HR+/HER2- BC. While the financials for the Q were good, much of the discussion on the call was forward-looking. Key questions centered on Trodelvy's path forward in HR+/HER2- BC, the potential impact of proposed Medicare drug pricing legislation, and the upcoming data read-outs. The story remains somewhat challenging, as near-term the business is fine, but we've yet to see how the true next leg of growth materializes. Reiterate Mkt."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $59.54 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• BMO Capital Reiterates Outperform Rating on Netflix (NFLX), Advertising Seen As a Key Lever
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• McGraw Hill (MH) PT Raised to $15 at UBS